California State Teachers Retirement System Sells 110,266 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

California State Teachers Retirement System trimmed its holdings in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 8.2% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,241,262 shares of the company's stock after selling 110,266 shares during the period. California State Teachers Retirement System owned about 0.11% of Teva Pharmaceutical Industries worth $27,357,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Robeco Institutional Asset Management B.V. boosted its stake in shares of Teva Pharmaceutical Industries by 7.2% during the 4th quarter. Robeco Institutional Asset Management B.V. now owns 498,309 shares of the company's stock worth $10,983,000 after buying an additional 33,277 shares during the last quarter. Pinnbrook Capital Management LP acquired a new position in shares of Teva Pharmaceutical Industries during the 4th quarter worth about $4,966,000. Asset Management One Co. Ltd. boosted its stake in shares of Teva Pharmaceutical Industries by 14.6% during the 4th quarter. Asset Management One Co. Ltd. now owns 457,371 shares of the company's stock worth $10,414,000 after buying an additional 58,413 shares during the last quarter. Allspring Global Investments Holdings LLC boosted its stake in shares of Teva Pharmaceutical Industries by 2,018.3% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,097,096 shares of the company's stock worth $23,368,000 after buying an additional 1,045,305 shares during the last quarter. Finally, Capital Wealth Planning LLC boosted its stake in shares of Teva Pharmaceutical Industries by 8.8% during the 4th quarter. Capital Wealth Planning LLC now owns 246,601 shares of the company's stock worth $5,435,000 after buying an additional 20,016 shares during the last quarter. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Price Performance

NYSE:TEVA traded up $0.48 during mid-day trading on Monday, reaching $17.26. The stock had a trading volume of 9,478,222 shares, compared to its average volume of 10,103,109. The stock has a 50-day simple moving average of $15.55 and a two-hundred day simple moving average of $17.38. The stock has a market capitalization of $19.56 billion, a PE ratio of -11.90, a P/E/G ratio of 1.44 and a beta of 0.62. Teva Pharmaceutical Industries Limited has a 12 month low of $12.47 and a 12 month high of $22.80. The company has a debt-to-equity ratio of 2.97, a current ratio of 0.98 and a quick ratio of 0.75.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its earnings results on Wednesday, May 7th. The company reported $0.52 earnings per share for the quarter, topping analysts' consensus estimates of $0.47 by $0.05. The firm had revenue of $3.89 billion for the quarter, compared to analysts' expectations of $3.99 billion. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. The company's revenue was up 1.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.48 earnings per share. On average, equities analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current year.

Analyst Ratings Changes

TEVA has been the subject of a number of recent research reports. Wall Street Zen upgraded shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research note on Thursday, May 22nd. Hsbc Global Res upgraded shares of Teva Pharmaceutical Industries to a "strong-buy" rating in a research note on Monday, April 28th. Truist Financial assumed coverage on shares of Teva Pharmaceutical Industries in a research note on Wednesday, May 28th. They issued a "buy" rating and a $25.00 target price for the company. JPMorgan Chase & Co. upgraded shares of Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and raised their target price for the company from $21.00 to $23.00 in a research note on Monday, May 12th. Finally, Bank of America raised their target price on shares of Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the company a "buy" rating in a research note on Thursday, May 8th. Eight equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus price target of $24.50.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.